Dark Streaming/Mobile Old Site Home Products Help Contact Us Your Account System Status
Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS
14:22:15 EDT Mon 29 Apr 2024
Enter Symbol
or Name
USA
CA



Q:BLRX - BIOLINE RX LTD SPON ADS EACH REPR 15 ORD SHS - http://www.biolinerx.com
Sym-XBid - AskLastChg%ChVol$Vol#TrOpen-Hi-LoYear Hi-LoLast TrNewsDelay
BLRX - Q0.10.6454·0.65010.10.6504+0.03886.3294.11653560.6257  0.6575  0.60092.53  0.560614:01:21Apr 1715 min RT 2¢

Recent Trades - Last 10 of 356
Time ETExPriceChangeVolume
14:01:21Q0.650.03841
14:00:34Q0.650.03841
13:59:54Q0.65010.03851
13:59:27Q0.650.03841
13:54:47Q0.65040.0388100
13:53:37Q0.65050.0389100
13:53:37Q0.65050.0389100
13:53:01Q0.650.0384100
13:53:01Q0.65220.040618
13:52:59Q0.65370.0421200

Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS

Recent Bulletins
Date ETSymbolTypeHeadline
2024-04-17 07:00U:BLRXNews ReleaseBioLineRx Announces Poster Presentation on Apheresis Center Efficiency and CXCR4 Antagonists including APHEXDA(TM) (motixafortide) in Patients with Multiple Myeloma at the ASFA 2024 Annual Meeting
2024-04-10 07:00U:BLRXNews ReleaseBioLineRx Accesses Second Tranche of $20 Million Under Previously Announced $40 Million Non-Dilutive Debt Financing Agreement
2024-04-01 09:00U:BLRXNews ReleaseBioLineRx Announces $6 Million Registered Direct Offering
2024-03-26 07:00U:BLRXNews ReleaseBioLineRx Reports 2023 Financial Results and Recent Corporate and Portfolio Updates
2024-03-20 07:00U:BLRXNews ReleaseBioLineRx to Report 2023 Annual Financial Results on March 26, 2024
2024-03-04 07:00U:BLRXNews ReleaseBioLineRx Strengthens Intellectual Property Estate with Notice of Allowance for U.S. Patent Covering Method of Manufacturing Motixafortide (BL-8040) Suitable for Large Scale Production
2024-02-28 07:00U:BLRXNews ReleaseBioLineRx Announces First Patient Dosed in Randomized Phase 2 Combination Clinical Trial Evaluating Motixafortide in First-Line Pancreatic Cancer (PDAC)
2024-02-16 07:00U:BLRXNews ReleaseBioLineRx Announces Acceptance of Two Poster Presentations on APHEXDA ‚ ® (motixafortide) for CD34+ Hematopoietic Stem Cell (HSC) Mobilization in Patients with Multiple Myeloma at the 2024 Tandem Meetings of ASTCT ‚ ® and CIBMTR ‚ ®
2023-12-21 07:00U:BLRXNews ReleaseBioLineRx Announces First Patient Dosed in Phase 1 Clinical Trial Evaluating Motixafortide for CD34+ Hematopoietic Stem Cell Mobilization for Gene Therapies in Sickle Cell Disease
2023-11-20 07:00U:BLRXNews ReleaseBioLineRx Reports Third Quarter 2023 Financial Results and Recent Corporate and Portfolio Updates
2023-11-13 07:00U:BLRXNews ReleaseBioLineRx to Report Third Quarter 2023 Results on November 20, 2023
2023-10-31 09:00U:BLRXNews ReleaseBioLineRx entered Exclusive License Agreement to Motixafortide in Asia, advisored by M.S.Q. Ventures
2023-10-12 07:00U:BLRXNews ReleaseBioLineRx Announces Closing of Exclusive License Agreement to Motixafortide in Asia and Concurrent Strategic Equity Investment
2023-09-28 07:00U:BLRXNews ReleaseBioLineRx Announces Encouraging Data from Pilot Phase of Phase 2 Combination Clinical Trial with Motixafortide in First-Line Pancreatic Cancer (PDAC)
2023-09-19 07:00U:BLRXNews ReleaseBioLineRx Announces Acceptance of Oral Presentation on Pilot Phase Data from Phase 2 Combination Clinical Trial with Motixafortide in First-Line PDAC at AACR Special Conference on Pancreatic Cancer
2023-09-11 07:00U:BLRXNews ReleaseBioLineRx Announces FDA Approval of APHEXDA ¢ „ ¢ (motixafortide) in Combination with Filgrastim (G-CSF) to Mobilize Hematopoietic Stem Cells for Collection and Subsequent Autologous Transplantation in Patients with Multiple Myeloma
2023-08-30 07:00U:BLRXNews ReleaseBioLineRx Reports Second Quarter 2023 Financial Results and Recent Corporate and Portfolio Updates
2023-08-22 07:00U:BLRXNews ReleaseBioLineRx to Report Second Quarter 2023 Results on August 30, 2023
2023-07-17 07:00U:BLRXNews ReleaseBioLineRx Announces Initiation of Randomized Phase 2 Clinical Trial in First Line Metastatic Pancreatic Cancer Based on Preliminary Data from Single-Arm Pilot Phase; Combination Trial Includes Investigational Candidate Motixafortide